The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Elahere is the first drug to improve survival in platinum-resistant ovarian cancer. "Ovarian cancer can be devastating and, when cancer cells stop responding to chemotherapy, patients may feel ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of ...

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer ...

Lantern Pharma Inc. , an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received ...

Up to that point, Young had believed that as long as she worked hard enough, she could achieve almost anything she wanted: “I ...

A gene expression map in monkeys has shown that drug effectiveness, alcohol tolerance and carbohydrate metabolism all vary ...